GlassScriptPhysician profile
Mark J Goldstein
NPI 1902947484
$2,774.23
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,585 · 2020: $79.31 · 2021: $60.85 · 2022: $49.44.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $1,554.43 | 2019-2021 | |
| Pfizer INC. | $464.55 | 2019-2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $282.94 | 2019-2020 | |
| Journey Medical Corporation | $203.32 | 2019 | |
| Almirall LLC | $81.06 | 2019 | |
| Gilead Sciences, INC. | $77.96 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $17.70 | 2019 | |
| Sebela Pharmaceuticals INC. | $17.30 | 2019 | |
| Sun Pharmaceutical Industries INC. | $16.03 | 2022 | |
| Celgene Corporation | $15.36 | 2019 | |
| Taro Pharmaceuticals USA, INC. | $14.95 | 2019 | |
| Encore Dermatology INC. | $14.61 | 2019 | |
| Mission Pharmacal Company | $14.02 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Goldstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.